What a New Phase 1 Stem Cell Study May Mean for Knee Osteoarthritis

A recently published Phase 1 clinical trial from Korean biotech company Kangstem Biotech is generating interest in the regenerative medicine community for its early findings in knee osteoarthritis (OA). The study evaluated an investigational therapy called OSCA, which combines umbilical cord blood–derived mesenchymal stem cells (MSCs) with an acellular cartilage matrix (a cell-free cartilage scaffold designed to support tissue repair). Early MRI findings suggested possible structural improvements in cartilage, alongside improvements in pain and function.

While these results are preliminary and not proof of cartilage regrowth, they contribute to a growing body of research exploring how cell-based therapies may support joint preservation and symptom management in osteoarthritis.

What Did the Study Show?

According to the published report, the Phase 1 trial enrolled 12 patients with knee osteoarthritis in a multicenter dose-escalation study. The primary goal of a Phase 1 study is to evaluate safety and tolerability, not to prove effectiveness.

Researchers reported:

• No dose-limiting toxicities
• Mostly mild to moderate adverse events
• Improvements in pain and functional outcome measures at 24 weeks
• MRI-based changes that may suggest structural cartilage improvement in the mid- and high-dose groups

Importantly, the authors described these MRI findings as “suggestive” of cartilage repair activity. Larger, controlled studies will be needed to determine whether these imaging changes translate into durable cartilage regeneration and meaningful long-term clinical benefit.

Why Umbilical Cord–Derived MSCs Are Receiving Attention

Umbilical cord blood–derived MSCs are being studied because they may offer several potential advantages in regenerative medicine research, including:

• Strong proliferative capacity
• Lower immunogenicity
• Ability to produce signaling molecules involved in tissue repair and immune modulation

These therapies are considered “allogeneic,” meaning the cells come from donor tissue rather than the patient themselves.

Several cord blood–derived MSC products have already been studied internationally. One of the most notable examples is CARTISTEM, a therapy approved in South Korea for certain cartilage defects. Long-term follow-up studies on CARTISTEM have reported sustained symptom improvement and imaging findings consistent with hyaline-like cartilage repair in some patients.

However, it is important to note that regulatory approval, indications, and available evidence vary significantly between countries. Most of these therapies remain investigational in the United States.

What MRI Findings Can and Cannot Tell Us

MRI imaging is an important tool in osteoarthritis research because it allows investigators to evaluate cartilage thickness, joint structure, and tissue quality over time.

That said, MRI changes alone do not necessarily prove that fully functional cartilage has regenerated. Researchers still need to determine:

• Whether new tissue behaves like healthy cartilage
• How durable the changes are over time
• Which patients may benefit most
• Whether improvements outperform placebo or standard care in larger randomized trials

This is why early-stage regenerative medicine studies should be interpreted carefully. Promising imaging findings are encouraging, but they are not the same as definitive clinical proof.

The Bigger Picture in Regenerative Orthopedics

The Kangstem study reflects a broader trend in orthobiologics and regenerative medicine research: the search for therapies that may help preserve joints earlier in the disease process and potentially delay more invasive interventions.

Researchers worldwide are investigating other biologic treatments such as:

• Platelet-rich plasma (PRP)
• Bone marrow concentrate
• Adipose-derived cell therapies

Some early studies have shown encouraging signals, particularly for symptom relief and functional improvement, but the field continues to evolve. More large-scale, high-quality clinical trials are still needed to clarify safety, effectiveness, ideal patient selection, and long-term outcomes.

At Orthohealing, a leading regenerative medicine clinic, we closely follow emerging research like this to help inform an evidence-based approach to patient care. Our focus remains on integrating the most current scientific developments with advanced regenerative therapies to support healing, mobility, and long-term musculoskeletal health.

Our team takes a personalized, patient-centered approach to care—combining advanced imaging, innovative biologic treatments, and manageable rehabilitation strategies designed to minimize symptoms and increase quality of life.

If knee osteoarthritis, chronic joint pain, or a sports-related injury is limiting your activity, find out if our therapies may be right for you. Schedule a consultation to explore potential options for restoring joint health and moving with greater strength, ease, and confidence.

 Call: (310) 453-5404
 Book online
 Follow us on Instagram